CHMP nod for two MicardisPlus generics and generic Ebixa
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's scientific advisory board, the CHMP, has given the go-ahead for three generic drugs: both Krka and Actavis' versions of Boehringer Ingelheim's MicardisPlus (telmisartan plus hydrochlorothiazide) and Krka's version of Lundbeck's Ebixa (memantine).